Ariad Pharmaceuticals Inc fka ARIA

[biotech_researcher]

Actually: Ridaforolimus is described by investigators as a best-in-class mTOR with predictable MTD and
optimal therapeutic index.

From Barclay's recent report:
Ariad Pharmaceuticals
Upcoming Events
• Final analysis of Ridaforolimus Phase 3 SUCCEED trial in 4Q10
• Ridaforolimus preliminary Phase 2 data in endometrial cancer in 2H10
• Finalize either 45mg or 60mg dose selection for -534 with the new tablet form
• Update on discussions with regulatory agencies (FDA and EMEA) around AP-534 registration trial
• Initiation of -534 pivotal trial in 2H10
Key Laterals - Bristol Myers (Sprycel), Novartis (Gleevec and Tasigna). Chemgenex (Omacetaxine), Merck (partner)
Key Issues
Ridaforolimus opportunity in cancer with partner Merck - Substantial proof-of-concept for mTOR inhibition has been established with
approval for Torisel and Afinitor in RCC. Ridaforolimus is described by investigators as a best-in-class mTOR with predictable MTD and
optimal therapeutic index. Durable clinical benefit response (CBR) of 30% in sarcoma should support SUCCEED success on the final PFS
analysis in 4Q10.